ACET 0.83 ▲ 0.25% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Adicet Bio Inc.

    NASDAQ: ACET · Real-Time Price · USD
    0.83
    0.00 (0.25%)
    At close: Oct 03, 2025, 3:59 PM
    0.85
    1.86%
    After-hours: Oct 03, 2025, 07:55 PM EDT
    0.25%
    Bid 0.79
    Market Cap 69.48M
    Revenue (ttm) 6.51M
    Net Income (ttm) -118.64M
    EPS (ttm) -1.32
    PE Ratio (ttm) -0.63
    Forward PE -0.79
    Analyst Buy
    Dividends n/a
    Ask 0.85
    Volume 871,754
    Avg. Volume (20D) 477,423
    Open 0.80
    Previous Close 0.83
    Day's Range 0.80 - 0.84
    52-Week Range 0.45 - 1.54
    Beta 1.63
    Ex-Dividend Date n/a

    About ACET

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol ACET
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for ACET stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts
    5 months ago
    -18.65%
    Adicet Bio shares are tracing lower. The company r... Unlock content with Pro Subscription
    8 months ago
    +9.79%
    Adicet Bio shares are trading higher after the company was granted FDA Fast Track designation to ADI-001 for treating refractory systemic lupus erythematosus with extrarenal involvement.
    news image

    4 days ago · businesswire.com

    Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

    REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun...

    news image

    5 days ago · zacks.com

    Adicet Bio (ACET) Upgraded to Buy: Here's What You Should Know

    Adicet Bio (ACET) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

    news image

    1 month ago · businesswire.com

    Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun...

    news image

    1 month ago · zacks.com

    Adicet Bio (ACET) Upgraded to Buy: Here's Why

    Adicet Bio (ACET) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

    news image

    2 months ago · businesswire.com

    Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference

    REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun...

    news image

    2 months ago · businesswire.com

    Adicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases

    REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun...

    Add to Watchlist